SCHEMBL2743876

SCHEMBL2743876

COc1ccc(/C=C/C(=O)/C=C/c2ccc(OC)c(OC)c2)cc1OC

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 2/20 0.79
JUN P05412 1/20 0.79
KDM4E B2RXH2 2/20 0.77
ALDH1A1 P00352 2/20 0.77
HPGD P15428 1/20 0.77
ALOX15 P16050 1/20 0.77
MAPK1 P28482 1/20 0.77
SMN1; SMN2 Q16637 1/20 0.77
HSD17B10 Q99714 1/20 0.77
CYP1A2 P05177 3/20 0.75
CYP2D6 P10635 3/20 0.75
NFE2L2 Q16236 2/20 0.75
ALOX5 P09917 1/20 0.75
HSD11B1 P28845 1/20 0.75
STAT3 P40763 1/20 0.75
NFKB2 Q00653 1/20 0.75
RELA Q04206 1/20 0.75
CA2 P00918 2/20 0.73
KMT2A Q03164 3/20 0.73
ABCG2 Q9UNQ0 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30493821 1.00 NFKB1 (0.79) NFKB1JUNKDM4EALDH1A1HPGD
SCHEMBL2743877 1.00 NFKB1 (0.79) NFKB1JUNKDM4EALDH1A1HPGD
SCHEMBL2744663 0.92 NFKB1 (0.74) NFKB1JUNKDM4EALDH1A1HPGD
SCHEMBL13039663 0.92 KDM4E (0.82) NFKB1JUNKDM4EALDH1A1HPGD
SCHEMBL28356985 0.92 CYP2D6 (0.69) NFKB1JUNKDM4EALDH1A1HPGD
SCHEMBL2744234 0.92 CYP2D6 (0.91) NFKB1JUNKDM4EALDH1A1HPGD
SCHEMBL2744668 0.92 NFKB1 (0.74) NFKB1JUNKDM4EALDH1A1HPGD
SCHEMBL2744233 0.92 CYP2D6 (0.91) NFKB1JUNKDM4EALDH1A1HPGD
SCHEMBL2744131 0.92 NFKB1 (0.68) NFKB1JUNKDM4EALDH1A1HPGD
SCHEMBL14982038 0.92 NFKB1 (0.68) NFKB1JUNKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432401-B2 Method for the preparation of 1,5-bis(4-hydroxy-3-metoxy-phenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties Fundação de Amparo a Pesquisa Do Estado de São Paulo (BR) 2008-10-07 US claimed
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2022-05-19 US disclosed
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2020-12-10 US disclosed
US-10799552-B2 Methods for treating diabetic neurotherapy MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2020-10-13 US disclosed
US-10751330-B2 Human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2020-08-25 US disclosed
US-10744124-B2 Human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2020-08-18 US disclosed
EP-2560629-B1 METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS MASSACHUSETTS EYE & EAR INFIRMARY (US) 2020-06-03 EP disclosed
US-20200147061-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2020-05-14 US disclosed
EP-3275465-B1 THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT ANKH LIFE SCIENCES LTD (IE) 2020-05-06 EP disclosed
US-10639345-B2 Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2020-05-05 US disclosed
US-7355081-B2 androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2008-04-08 US disclosed
US-7355081-B2 androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2008-04-08 US disclosed
WO-2007075772-A2 COMPOUNDS, SCREENS, AND METHODS OF TREATMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-07-05 WO disclosed
US-20070060644-A1 Therapeutic curcumin derivatives STC.UNM 2007-03-15 US disclosed
US-20070060644-A1 Therapeutic curcumin derivatives STC.UNM 2007-03-15 US disclosed
US-20060276536-A1 Cancer treatment using curcumin derivatives STC.UNM 2006-12-07 US disclosed
US-20060128997-A1 New method for the preparation of 1,5-bis(4-hydroxy-3-metoxy-phenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO (BR) 2006-06-15 US disclosed
EP-1572614-A2 NEW METHOD FOR THE PREPARATION OF 1,5-BIS(4-HYDROXY-3-METOXY-PHENYL)-PENTA-1,4-DIEN-3-ONE AND DERIVATIVES WITH ANTITUMORAL PROPERTIES Fundacio de Amparo Pesquisa do Estado des Sao Paulo (BR) 2005-09-14 EP disclosed
WO-2004047716-A2 NEW METHOD FOR THE PREPARATION OF 1,5-BIS(4-HYDROXY-3-METOXY-PHENYL)-PENTA-1,4-DIEN-3-ONE AND DERIVATIVES WITH ANTITUMORAL PROPERTIES Fundação De Amparo À Pesquisa Do Estado de São Paulo (BR) 2004-06-10 WO disclosed
US-RE29358-E ANTI-MALARIA AND ANTI-TUBERCULOSIS AGENTS AMERICAN CYANAMID COMPANY (US) 1977-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10744124-B2 Human therapeutic agents INMT, HNMT, HASPIN NFKB1 841/4885JUN 2377/4885KDM4E 3586/4885
US-20070060644-A1 Therapeutic curcumin derivatives FABP2, GLS2, FABP1 NFKB1 418/4885JUN 2204/4885KDM4E 3658/4885
US-20060128997-A1 New method for the preparation of 1,5-bis(4-hydroxy-3-metoxy-phenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties DDB1, ANXA1, ANXA5 NFKB1 310/4885JUN 3433/4885KDM4E 2890/4885
US-10751330-B2 Human therapeutic agents INMT, HNMT, HASPIN NFKB1 841/4885JUN 2377/4885KDM4E 3586/4885
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN NFKB1 841/4885JUN 2377/4885KDM4E 3586/4885
US-20200147061-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN NFKB1 841/4885JUN 2377/4885KDM4E 3586/4885
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN NFKB1 841/4885JUN 2377/4885KDM4E 3586/4885
US-10799552-B2 Methods for treating diabetic neurotherapy NGF, NTRK2, BDNF NFKB1 1775/4885JUN 2556/4885KDM4E 4068/4885
US-20060276536-A1 Cancer treatment using curcumin derivatives BRCA1, VHL, TP53 NFKB1 73/4885JUN 786/4885KDM4E 2055/4885
US-10639345-B2 Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function ALDH1A2, PDE6B, PDE6A NFKB1 2097/4885JUN 4631/4885KDM4E 4589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.